Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) FCF Margin: 2022-2025

Historic FCF Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -143.52%.

  • InMed Pharmaceuticals' FCF Margin rose 93.00% to -143.52% in Q3 2025 from the same period last year, while for Sep 2025 it was -157.31%, marking a year-over-year decrease of 2348.00%. This contributed to the annual value of -157.14% for FY2025, which is 500.00% down from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' FCF Margin is -143.52%, which was down 5.29% from -136.31% recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year FCF Margin high stood at -29.85% for Q2 2023, and its period low was -1,728.88% during Q1 2022.
  • Its 3-year average for FCF Margin is -146.02%, with a median of -144.45% in 2024.
  • Per our database at Business Quant, InMed Pharmaceuticals' FCF Margin spiked by 156,865bps in 2023 and then slumped by 7,605bps in 2024.
  • Quarterly analysis of 4 years shows InMed Pharmaceuticals' FCF Margin stood at -577.52% in 2022, then skyrocketed by 42,850bps to -149.02% in 2023, then plummeted by 7,605bps to -225.07% in 2024, then skyrocketed by 93bps to -143.52% in 2025.
  • Its last three reported values are -143.52% in Q3 2025, -136.31% for Q2 2025, and -131.54% during Q1 2025.